Dr. Kakar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
14211 Commerce Way
Miami Lakes, FL 33016Phone+1 888-852-6672Fax+1 305-891-4228- Is this information wrong?
Summary
- I am board certified psychiatrist with additional training from National Institute of Mental Health. I am currently a Medical Director for a large research institute a and primary investigator for numerous phase I- IV clinical trials. I am actively conducting studies in depression,anxiety, bipolar, schizophrenia, pain, dementia and
substance use. I also have a clinical practice where I see adults and adolescents with various psychiatric disorders. I am especially interested in integrating mind body approaches, nutritional methods, ortho molecular techniques along with traditional pharmacological regimen to treat my patients.
Education & Training
- Clinical Center at the National Institutes of HealthFellowship, Psychosomatic Medicine, 2010 - 2011
- MedStar Health/Georgetown University HospitalResidency, Psychiatry, 2008 - 2010
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Neurology, 2007 - 2007
- Saint Peter's University Hospital/Rutgers Robert Wood Johnson Medical SchoolInternship, Internal Medicine, 2006 - 2007
- Albany Medical CollegeClass of 2006
Certifications & Licensure
- CA State Medical License 2017 - Present
- FL State Medical License 2011 - 2025
- MD State Medical License 2010 - 2012
- DC State Medical License 2008 - 2010
- PA State Medical License 2007 - 2008
- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- FL Top Doctor Award 2018
- Elected member Alpha Omega Alpha, 2006
Clinical Trials
- Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia Start of enrollment: 2008 Sep 01
- Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD) Start of enrollment: 2012 Nov 01
- Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Start of enrollment: 2013 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsEfficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, p...Kaul, I., Sawchak, S., Zhu, H., Miller, A., Paul, S., Brannan, S., Correll, C., Kakar, R., Breier, A.> ;Lancet. 2024 Jan 13
- 7 citationsSublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.Leslie Citrome, Sheldon H Preskorn, John Lauriello, John H Krystal, Rishi Kakar, Jeffrey Finman, Michael De Vivo, Frank D Yocca, Robert Risinger, Lavanya Rajachandran> ;The Journal of Clinical Psychiatry. 2022 Oct 3
- 2 citationsSublingual Dexmedetomidine vs Placebo and Acute Agitation Associated With Bipolar Disorder-Reply.Sheldon H Preskorn, Robert Risinger, Rishi Kakar> ;JAMA. 2022 Jul 12
- Join now to see all
Journal Articles
- FIRST Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-bl...Inder Kaul, MD Sharon Sawchak, RN Prof Christoph U Correll, MD Rishi Kakar, MD Prof Alan Breier, MD Haiyuan Zhu, PhD Andrew C Miller, PhD Steven M Paul, MD Stephen K ..., The Lancet, 12/14/2023
Abstracts/Posters
- Translational Research with Dexmedetomidine (DM) for the Treatment of Agitation from Healthy Volunteers to Two Patient groups: Those with Schizophrenia or with Probabl...Sheldon Preskorn , Rishi Kakar , Hrishikesh Kumar , Sameer Sharma† , Vince O’Neill† , Robert Risinger† , Frank Yocca†, American Society of Clinical Psychopharmacology, Scottsdale, AZ, 5/2019
- Clinical training in Neurosciences: NIMH perspectiveKakar, R. Akil, M, Pao, M, Journal of Biological Psychiatry, 4/2011
Press Mentions
- Human Trials for General Anxiety Disorder Involve LSD CompoundOctober 3rd, 2022
- Miami Clinic Kicks off First National Study of LSD, Once a ‘Public Enemy,’ to Treat AnxietySeptember 22nd, 2022
- Karuna Therapeutics Scores Phase 3 Win for Schizophrenia Therapy KarXTAugust 9th, 2022
- Join now to see all
Research History
- Research Fellow, NIMHPsychosomatic fellow/Georgetown Resident2010 - 2011
Hospital Affiliations
- Plantation General HospitalFort Lauderdale, Florida
- Westside Regional Medical CenterFort Lauderdale, Florida
- HCA Florida Aventura HospitalMiami, Florida
Industry Relationships
- Speaker/Consultant, Otsuka LUNDBECK2017 - 2020
- Coordinating Investigator, Eli LillyCoordinating investigator, medical review 15-MJ- NOAC clinical study2014 - 2014
- Consultant, Neurocrine Biosciences2013 - 2014
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: